Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMPERO benralizumab in uncontrolled asthma
2013-002352-32Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Benralizumab add-on with Placebo add-on (2 arms). Primary endpoint: Annual asthma exacerbation rate. Started Sep 2013; status: terminated.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-002352-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002352-32.